TROG 03.04 (RADAR)

Primary sponsor: Trans Tasman Radiation Oncology Group (TROG)

Title

A randomised trial investigating the effect on biomedical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definite radiation treatment for localised carcinoma of the prostate (RADAR)

Summary

Six months of hormone treatment improves the results of radiotherapy for men with early prostate cancer. This trial will determine if adding another 12 months of hormone treatment after radiotherapy is even better. Bones are often affected by prostate cancer and can also be damaged by prolonged hormone treatment. Bisphosphonates are drugs that make bones stronger. This trial will also determine if treatment with a bisphosphonate can help prevent these bone problems.

Final accrual

1071

Trial Status

Closed to Accrual, August 2007

Trial chairperson

Prof Jim Denham, Calvary Mater Newcastle, NSW

Trial contact

Allison Steigler
Prostate Cancer Trials Group
Email: Allison.Steigler@newcastle.edu.au
Tel: 02 4985 4019

Further information

TROG 03.04 on Australian Cancer Trials website

Media announcements

Media release - 'New prostate treament prevents cancer spread' - Fri 15 August, 2014: "Australian and New Zealand researchers have discovered a powerful new prostate cancer treatment regime that can reduce the spread of aggressive but apparently localised tumours by more than 40 per cent. The 5 year follow up results of the Trans-Tasman Radiation Oncology Group 03.04 RADAR trial give Australian and New Zealand men with newly-diagnosed cancer a better chance of survival without increased long term side effects."

Trial resources for TROG members

TROG 03.04 member page